北美内镜黏膜下剥离术:大型前瞻性多中心研究
整块切除率、R0切除率和治愈性切除率分别为91.5%、84.2%和78.3%,出血和穿孔发生率分别为2.3%和2.9%,平均随访13.3个月复发率为5.8%。研究表明ESD在北美可安全有效开展,复发率低。
要点
- ESD整块切除率91.5%、R0切除率84.2%、治愈性切除率78.3%。
- 出血和穿孔发生率分别为2.3%和2.9%,仅1例(0.14%)需手术处理不良事件。
- 严重黏膜下纤维化与整块、R0及治愈性切除失败及更高不良事件风险相关。
核心结论
- 在北美大型多中心前瞻性研究中,ESD可安全、有效地实施,且复发率低。
- 本研究达到的技术切除结局与当前公认的共识质量参数一致,支持ESD用于治疗选择性胃肠道肿瘤。
研究设计与样本
- 患者中位年龄66岁,57.8%为男性,病变中位大小40 mm(四分位距25-52 mm)。
- 病变部位包括食管(n=181)、胃(n=101)、十二指肠(n=11)、结肠(n=211)和直肠(n=188)。
主要发现
- 整块切除率、R0切除率和治愈性切除率分别为91.5%、84.2%和78.3%。
- 出血和穿孔发生率分别为2.3%和2.9%,仅1例患者(0.14%)因不良事件需手术。
- 多变量分析显示,严重黏膜下纤维化与整块、R0及治愈性切除失败相关,并与更高不良事件风险相关。
- 平均随访13.3个月(范围1-60个月),总体复发率为5.8%(31/532)。
临床怎么用
- ESD可用于北美选择性胃肠道肿瘤的治疗,技术结局与既定共识质量参数一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Endoscopic submucosal dissection (ESD) in Asia has been shown to be superior to endoscopic mucosal resection (EMR) and surgery for the management of selected early gastrointestinal cancers. We aimed to evaluate technical outcomes of ESD in North America. METHODS: We conducted a multicenter prospective study on ESD across 10 centers in the United States and Canada between April 2016 and April 2020. End points included rates of en bloc resection, R0 resection, curative resection, adverse events, factors associated with failed resection, and recurrence post-R0 resection. RESULTS: Six hundred and ninety-two patients (median age, 66 years; 57.8% were men) underwent ESD (median lesion size, 40 mm; interquartile range, 25-52 mm) for lesions in the esophagus (n = 181), stomach (n = 101), duodenum (n = 11), colon (n = 211) and rectum (n = 188). En bloc, R0, and curative resection rates were 91.5%, 84.2%, and 78.3%, respectively. Bleeding and perforation were reported in 2.3% and 2.9% of the cases, respectively. Only 1 patient (0.14%) required surgery for adverse events. On multivariable analysis, severe submucosal fibrosis was associated with failed en bloc, R0, and curative resection and higher risk for adverse events. Overall recurrence was 5.8% (31 of 532) at a mean follow-up of 13.3 months (range, 1-60 months). CONCLUSIONS: In this large multicenter prospective North American experience, we demonstrate that ESD can be performed safely, effectively, and is associated with a low recurrence rate. The technical resection outcomes achieved in this study are in line with the current established consensus quality parameters and further support the implementation of ESD for the treatment of select gastrointestinal neoplasms; ClinicalTrials.gov, Number: NCT02989818.
引用
- Draganov PV, Aihara H, Karasik MS, et al. Endoscopic Submucosal Dissection in North America: A Large Prospective Multicenter Study. Gastroenterology. 2021. PMID: 33610532. doi:10.1053/j.gastro.2021.02.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。